Food Noise on Mounjaro 5 mg, and When to Step Up

Food noise that returns on days 6 and 7 of a Mounjaro 5 mg week lines up with the weekly low in drug level, just before your next shot (Mounjaro label, section 5.2). The UK label lists 5 mg as a maintenance dose, and allows 7.5 mg "if needed" after at least 4 weeks on it (label, section 4.2).

Key facts

• Tirzepatide’s half-life is about 5 days, so a week after a shot the modelled level is about 38% of its peak (Mounjaro label, section 5.2).
• When less than 5% is lost 6 months after reaching the highest tolerated dose, the label and NICE ask for a decision on continuing (label, 4.2; NICE TA1026).
• On the lowest maintenance dose in SURMOUNT-1, average weight loss was 16.0% at 72 weeks, and about one in ten people lost less than 5% (label, section 5.1).
• In two pooled weight trials, nausea affected 24.6% of people on the lowest maintenance dose, against 8.5% on placebo (label, section 4.8).

Days 6 and 7 of a Mounjaro 5 mg week

Tirzepatide peaks 8 to 72 hours after a shot and has a half-life of about 5 days, according to Mounjaro’s Summary of Product Characteristics (SmPC), the official UK prescribing document (Mounjaro SmPC, section 5.2). The level is highest early in the week and lowest on the day your next dose is due. Halving every 5 days leaves about 38% of the peak a week after the shot.

The SmPC does not report appetite by day of the week, so the link between that low point and hunger on days 6 and 7 is an inference from how the drug is cleared.

Exposure rises in proportion to the dose (SmPC, section 5.2). At a steady level, the low point on 7.5 mg is 1.5 times the low point on 5 mg. That is about 57% of the 5 mg peak (1.5 × 38%). The step from 5 mg to 7.5 mg also takes 4 weeks of weekly shots to settle (SmPC, section 5.2).

Enter your own shot dates in the GLP‑1 plotter to see where days 6 and 7 fall on your curve.

Which pattern is yours

Keep a daily 0 to 10 food-noise log with the day of your dosing week beside each score. After 2 weeks, every day of the week has at least two scores to compare against these patterns.

Tolerance means an effect fading at a steady dose. The SmPC reports it for the delay in stomach emptying caused by tirzepatide, which "diminishes over time" (Mounjaro SmPC, section 5.1).

Moving from 5 mg to 7.5 mg

Mounjaro starts at 2.5 mg for 4 weeks, moves to 5 mg, and can then rise in 2.5 mg steps to 15 mg, with at least 4 weeks on each dose (Mounjaro SmPC, section 4.2). Enter your 5 mg start date in the dose titration planner for your own earliest dates, or compare the Mounjaro ladder with other brands.

The SmPC does not define "if needed", so the step is a decision for you and your prescriber. The earliest date is 4 weeks after your first 5 mg dose. If you started 5 mg on 1 October, 7.5 mg can come on 29 October at the soonest. Bring your weights since starting 5 mg, and a note of whether appetite stays quiet for most of the week or only after the shot. Your loss on each dose, with its dates, is one line of the weight report when your weigh-ins are logged in Pensday.

In the pooled SURMOUNT-1 and SURMOUNT-2 trials, nausea was reported by 24.6% of people on 5 mg and 29.0% on 10 mg, against 8.5% on placebo (SmPC, section 4.8). It was most common while the dose was being raised, then eased (SmPC, section 4.8).

At 6 months on your highest tolerated dose, the SmPC requires a decision on continuing if you have not lost at least 5% of your starting weight (SmPC, section 4.2). NICE’s tirzepatide guidance for the NHS in England sets the same check (NICE TA1026, recommendation 1.2).

Is there a golden dose of Mounjaro?

We found no trial that identifies a single dose that works for everyone. SURMOUNT-1, which excluded people with diabetes, assigned 2,539 adults to 5, 10 or 15 mg or placebo for 72 weeks, including a 20-week dose-escalation period (Jastreboff et al., NEJM 2022). The UK label’s figures estimate what would have happened had no one stopped treatment (Mounjaro SmPC, section 5.1, table 9).

Half the people on 5 mg lost 15% or more. At the other end, 89.4% lost at least 5%, which leaves about one in ten who lost less (SmPC, section 5.1).

Eating on days 6 and 7

If the end of the week is when you graze, build those days' meals around protein. Raising protein from 15% to 30% of calories increased fullness and cut spontaneous intake by 441 kcal a day in a 2005 study of 19 adults (Weigle et al., 2005). The study ran before GLP‑1 medicines were used for weight loss. Split the daily target from the GLP‑1 protein calculator across the meals on those two days.

What the brain-recording case shows

A 2025 Nature Medicine case report describes one 60-year-old woman with type 2 diabetes and severe obesity despite bariatric surgery. She had electrodes in the nucleus accumbens, part of the brain’s reward system, as part of a deep brain stimulation trial (Choi et al., 2025).

On tirzepatide 12.5 mg and then 15 mg, severe food preoccupation was largely absent in months 2 to 4 after surgery and broke through in months 5 to 7. The authors call it "a single uncontrolled case study" (Choi et al., 2025).